⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for lazertinib

Every month we try and update this database with for lazertinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerNCT02609776
Non-Small-Cell ...
Amivantamab
Amivantamab
Lazertinib
Carboplatin
Pemetrexed
18 Years - Janssen Research & Development, LLC
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid BiopsyNCT05469022
Non Small Cell ...
Neoadjuvant laz...
19 Years - Konkuk University Medical Center
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentNCT06106802
Non-Small Cell ...
Lazertinib
Tepotinib
19 Years - Samsung Medical Center
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140
Carcinoma, Non-...
Amivantamab
Lazertinib
Doxycycline
Minocycline
Clindamycin
Chlorhexidine
Noncomedogenic ...
18 Years - Janssen Research & Development, LLC
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLCNCT05862194
Non-small Cell ...
Lazertinib
Platinum-based ...
18 Years - Yuhan Corporation
Impact of Lazertinib Dose Modification on Effectiveness and SafetyNCT05716672
Non-small Cell ...
Lazertinib
20 Years - Pusan National University Hospital
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669
Advanced or Met...
Lazertinib
Amivantamab Sub...
Amivantamab Int...
18 Years - Janssen Research & Development, LLC
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid MalignanciesNCT04606381
Advanced Solid ...
Ami-LC-MD
Ami-LC
Ami-HC
Ami-HC-CF
Lazertinib
18 Years - Janssen Research & Development, LLC
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid MalignanciesNCT04606381
Advanced Solid ...
Ami-LC-MD
Ami-LC
Ami-HC
Ami-HC-CF
Lazertinib
18 Years - Janssen Research & Development, LLC
Lazertinib 160mg in EGFR T790M NSCLCNCT05701384
Lung Cancer Sta...
EGFR T790M
Lazertinib
19 Years - Samsung Medical Center
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid BiopsyNCT05469022
Non Small Cell ...
Neoadjuvant laz...
19 Years - Konkuk University Medical Center
Premedication to Reduce Amivantamab Associated Infusion Related ReactionsNCT05663866
Carcinoma, Non-...
Dexamethasone
Montelukast
Methotrexate
Amivantamab
Lazertinib
18 Years - Janssen Research & Development, LLC
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid BiopsyNCT05469022
Non Small Cell ...
Neoadjuvant laz...
19 Years - Konkuk University Medical Center
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & SmokerNCT06156527
Lazertinib
Lazertinib
Bevacizumab Inj...
19 Years - National Cancer Center, Korea
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669
Advanced or Met...
Lazertinib
Amivantamab Sub...
Amivantamab Int...
18 Years - Janssen Research & Development, LLC
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsNCT05277701
NSCLC
Lazertinib
20 Years - Yonsei University
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid MalignanciesNCT04606381
Advanced Solid ...
Ami-LC-MD
Ami-LC
Ami-HC
Ami-HC-CF
Lazertinib
18 Years - Janssen Research & Development, LLC
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsNCT05299125
Metastatic Non-...
Amivantamab
Lazertinib
Pemetrexed 500 ...
18 Years - Latin American Cooperative Oncology Group
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung CancerNCT05377788
Metastatic Lung...
EGFR T790M
Lazertinib
19 Years - Samsung Medical Center
Impact of Lazertinib Dose Modification on Effectiveness and SafetyNCT05716672
Non-small Cell ...
Lazertinib
20 Years - Pusan National University Hospital
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsNCT05299125
Metastatic Non-...
Amivantamab
Lazertinib
Pemetrexed 500 ...
18 Years - Latin American Cooperative Oncology Group
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNCT06020989
Non Small Cell ...
Lazertinib+Peme...
Lazertinib
Lazertinib
19 Years - Yonsei University
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT05498428
Carcinoma, Non-...
Amivantamab
Lazertinib
Carboplatin
Pemetrexed
Direct Oral Ant...
Low Molecular W...
18 Years - Janssen Research & Development, LLC
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsNCT05277701
NSCLC
Lazertinib
20 Years - Yonsei University
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid MalignanciesNCT04606381
Advanced Solid ...
Ami-LC-MD
Ami-LC
Ami-HC
Ami-HC-CF
Lazertinib
18 Years - Janssen Research & Development, LLC
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyNCT05338619
Non-small Cell ...
EGFR Positive N...
Non-squamous No...
Lazertinib
18 Years - Korea University Guro Hospital
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)NCT04965090
Metastatic Non ...
Recurrent Non S...
Amivantamab
Lazertinib
18 Years - Memorial Sloan Kettering Cancer Center
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerNCT06268210
Non-small Cell ...
Lazertinib+Peme...
Lazertinib
20 Years - Yonsei University
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNCT06020989
Non Small Cell ...
Lazertinib+Peme...
Lazertinib
Lazertinib
19 Years - Yonsei University
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsNCT05277701
NSCLC
Lazertinib
20 Years - Yonsei University
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04487080
Carcinoma, Non-...
Amivantamab
Osimertinib
Lazertinib
Placebo
18 Years - Janssen Research & Development, LLC
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140
Carcinoma, Non-...
Amivantamab
Lazertinib
Doxycycline
Minocycline
Clindamycin
Chlorhexidine
Noncomedogenic ...
18 Years - Janssen Research & Development, LLC
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesNCT05477615
Non-small Cell ...
Lazertinib
Pemetrexed
Carboplatin
20 Years - Seoul St. Mary's Hospital
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)NCT04965090
Metastatic Non ...
Recurrent Non S...
Amivantamab
Lazertinib
18 Years - Memorial Sloan Kettering Cancer Center
AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKINCT05601973
Non Small Cell ...
Amivantamab
Lazertinib
Zirabev
18 Years - ETOP IBCSG Partners Foundation
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04487080
Carcinoma, Non-...
Amivantamab
Osimertinib
Lazertinib
Placebo
18 Years - Janssen Research & Development, LLC
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: